issu press releas receiv gadvair
june fda lower ep
gadvair delay partial off-set
biosimilar neulasta approv estimate bottom end
guidanc await updat
ir told us updat outlook would
report earn base convers ir receiv
provid updat compani said stand
management previous state june ir reiter revisit
outlook management would natur take consider impact
gadvair delay also posit develop happen recent eg
approv biosimilar neulasta
recal june disclos fda identifi minor defici
relay complet respons letter june releas
statement state afternoon june receiv updat
 food drug administr fda concern pend
approv gener advair disku fda identifi minor defici
relay complet respons letter june
abbrevi new drug applic receiv prioriti design
approv could receiv prior standard time period follow
date respons complet respons letter upon receipt
offici complet respons letter determin impact
could full year outlook
model gadvair launch novemb hope respond
within month secur fda approv month
know time look forward next updat
updat model reflect delay approv gadvair
partial off-set biosimilar neulasta approv assum potenti
gadvair launch odd novemb biosimilar neulasta launch
juli base chang lower ep
ep essenti remain unchang
estim ep vs con provid
quarterli guidanc specif ir tell us post earn
call may expect year second half weight addit
would point sequenti stronger usd eur could potenti
 unit state america
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
pose risk europ revenu recal europ
deliv yoy growth came fx gain sinc march
usd strengthen vs eur
maintain overweight stock rate maintain ow
trade low valuat ev/ebitda price-to-earnings multipl high singl
digit compani pipelin drive revenu ep growth
valuat methodolog risk
pt base ebitda target multipl within
rang pt impli target price-to-earnings project ebitda compound-annual-growth-rate
ep compound-annual-growth-rate
risk achiev price
greater expect gener price and/or volum pressur
addit competit epipen market
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report david
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
import us regulatori disclosur subject compani
may benefici own class common equiti secur follow compani cover morgan
within last month manag co-manag public offer offer secur
within last month receiv compens invest bank servic alkerm plc mylan inc
next month expect receiv intend seek compens invest bank servic alkerm plc allergan plc
within last month receiv compens product servic invest bank servic allergan plc
within last month provid provid invest bank servic invest bank client relationship
follow compani alkerm plc allergan plc depom inc plc horizon pharma plc
within last month either provid provid non-invest bank securities-rel servic and/or past
enter agreement provid servic client relationship follow compani alkerm plc allergan plc plc
 co llc make market secur plc allergan plc depom inc plc horizon pharma plc
equiti research analyst strategist princip respons prepar research receiv compens base upon
variou factor includ qualiti research investor client feedback stock pick competit factor firm revenu overal invest bank
revenu equiti research analyst strategist compens link invest bank capit market transact perform morgan
stanley profit revenu particular trade desk
affili busi relat companies/instru cover research includ market make provid
liquid fund manag commerci bank extens credit invest servic invest bank sell buy
custom securities/instru compani cover research princip basi may posit debt
compani instrument discuss report trade may trade princip debt secur relat deriv
subject debt research report
certain disclosur list also complianc applic regul non-u jurisdict
use rel rate system use term overweight equal-weight not-rat underweight see definit morgan
stanley assign rate buy hold sell stock cover overweight equal-weight not-rat underweight equival
buy hold sell investor care read definit rate use morgan stanley research addit sinc morgan stanley research
contain complet inform concern analyst view investor care read morgan stanley research entireti infer
content rate alon case rate research use reli upon invest advic investor decis buy sell
stock depend individu circumst investor exist hold consider
may
stock rate describ appli fundament equiti research appli debt research produc firm
disclosur purpos accord nasd nyse requir includ categori head buy hold sell alongsid
rate overweight equal-weight not-rat underweight assign rate buy hold sell stock cover
overweight equal-weight not-rat underweight equival buy hold sell repres recommend rel weight see
definit satisfi regulatori requir correspond overweight posit stock rate buy recommend correspond
equal-weight not-rat hold underweight sell recommend respect
data includ common stock adr current assign rate invest bank client compani receiv invest
bank compens last month due round decim percentag provid total column may add exactli
overweight stock total return expect exceed averag total return analyst industri industri team coverag univers
risk-adjust basi next month
equal-weight stock total return expect line averag total return analyst industri industri team coverag univers
risk-adjust basi next month
not-rat nr current analyst adequ convict stock total return rel averag total return analyst
industri industri team coverag univers risk-adjust basi next month
underweight stock total return expect averag total return analyst industri industri team coverag univers
risk-adjust basi next month
unless otherwis specifi time frame price target includ morgan stanley research month
attract analyst expect perform industri coverag univers next month attract vs relev broad
market benchmark indic
in-lin analyst expect perform industri coverag univers next month line relev broad market
benchmark indic
cautiou analyst view perform industri coverag univers next month caution vs relev broad market
benchmark indic
benchmark region follow north america latin america relev countri index latin america index europ
europ japan topix asia relev countri index sub-region index ac asia pacif ex japan index
stock price price target rate histori rate definit
import disclosur morgan stanley smith barney llc custom
